Strados Labs

Strados Labs specialises in three primary device categories: a cough ambulatory recording system for monitoring chronic cough symptoms, a battery charger designed specifically for noninvasive medical devices, and skin surface adhesives. Their flagship product, the Strados Labs Remote Electronic Stethoscope Platform (RESP), focuses on remote auscultation and digital recording of heart and lung sounds, enabling healthcare providers to assess patients remotely.

Strados Labs is based in the United States. Since the company’s devices are authorised under FDA regulations, their U.S. location aligns with the jurisdiction of the FDA’s 510(k) and Unique Device Identifier (UDI) pathways, which govern the classification and listing of their Class II devices in the FDA’s regulatory databases.

Strados Labs’ devices are classified as Class II under FDA regulations. This classification is typically assigned to devices that pose moderate risk and require special controls to ensure their safety and effectiveness. The company’s products, including the Remote Electronic Stethoscope Platform (RESP), fall into this category because they involve remote patient monitoring and noninvasive diagnostics, requiring validation of performance and usability without the higher risks associated with Class III devices.

Strados Labs’ devices are listed in the FDA’s regulatory databases through the 510(k) premarket notification process and the Unique Device Identifier (UDI) system. These pathways ensure that each device’s details, including its classification, intended use, and compliance status, are documented in the FDA’s official records for transparency and traceability.

The Strados Labs Remote Electronic Stethoscope Platform (RESP) is the company’s primary product, designed for remote auscultation and digital recording of heart and lung sounds. Its inclusion in the portfolio highlights Strados Labs’ focus on digital health solutions that enable remote patient monitoring, which is authorised under the FDA’s Class II classification. This platform exemplifies the company’s emphasis on noninvasive diagnostic tools that enhance clinical assessment capabilities.